 Adrenergic Uptake Inhibitors
"Adrenergic Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
| Descriptor ID |
D018759
|
| MeSH Number(s) |
D27.505.519.562.437.050 D27.505.519.625.050.601 D27.505.519.625.600.050 D27.505.696.577.050.601 D27.505.696.577.600.050
|
| Concept/Terms |
Adrenergic Uptake Inhibitors- Adrenergic Uptake Inhibitors
- Inhibitors, Adrenergic Reuptake
- Reuptake Inhibitors, Adrenergic
- Uptake Inhibitors, Adrenergic
- Adrenergic Reuptake Inhibitors
- Inhibitors, Adrenergic Uptake
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Uptake Inhibitors".
This graph shows the total number of publications written about "Adrenergic Uptake Inhibitors" by people in this website by year, and whether "Adrenergic Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic Uptake Inhibitors" by people in Profiles.
-
Burnham NW, Chaimowitz CN, Vis CC, Segantine Dornellas AP, Navarro M, Thiele TE. Lateral hypothalamus-projecting noradrenergic locus coeruleus pathway modulates binge-like ethanol drinking in male and female TH-ires-cre mice. Neuropharmacology. 2021 09 15; 196:108702.
-
Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
-
Johnson PL, Molosh A, Fitz SD, Arendt D, Deehan GA, Federici LM, Bernabe C, Engleman EA, Rodd ZA, Lowry CA, Shekhar A. Pharmacological depletion of serotonin in the basolateral amygdala complex reduces anxiety and disrupts fear conditioning. Pharmacol Biochem Behav. 2015 Nov; 138:174-9.
-
Novick AM, Forster GL, Hassell JE, Davies DR, Scholl JL, Renner KJ, Watt MJ. Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stress. Neuropharmacology. 2015 Oct; 97:194-200.
-
Ripley DL, Morey CE, Gerber D, Harrison-Felix C, Brenner LA, Pretz CR, Cusick C, Wesnes K. Atomoxetine for attention deficits following traumatic brain injury: results from a randomized controlled trial. Brain Inj. 2014; 28(12):1514-22.
-
Outhred T, Hawkshead BE, Wager TD, Das P, Malhi GS, Kemp AH. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neurosci Biobehav Rev. 2013 Sep; 37(8):1786-800.
-
Monte AA, Ceschi A, Bodmer M. Safety of non-therapeutic atomoxetine exposures--a national poison data system study. Hum Psychopharmacol. 2013 Sep; 28(5):471-6.
-
Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, Wilson JP. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol. 2012 Sep; 68(9):1295-302.
-
Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause. 2011 May; 18(5):542-8.
-
Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010 Jun; 49(6):573-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|